Biotech | September 16, 2025
Galimedix completes phase 1 study with oral small molecule GAL-101
The study further confirmed that GAL-101 effectively crosses the blood-brain barrier
The study further confirmed that GAL-101 effectively crosses the blood-brain barrier
Tagrisso plus chemotherapy achieves nearly four-year median overall survival in EGFR-mutated advanced lung cancer, setting new global standard in phase III trial
This approval follows the CDE’s clearance in July of this year for Phase 2/3 clinical studies of CB03-154 in amyotrophic lateral sclerosis
Products manufactured at the new Vaughan facility will support research in areas including cancer, infectious disease, mental health, and environmental safety
The HCl gas is generated continuously which is absorbed in the water scrubber using a chilled falling film system
Both will develop a non-viral manufacturing workflow designed to eliminate key bottlenecks and accelerate the delivery of lifesaving engineered cell therapies to patients
Program provides access to Lilly-trained artificial intelligence to help accelerate breakthrough medicines
MKP11093 has shown strong results in preclinical studies with a promising safety and selectivity profile
The Ma’anshan site approval covers pastilles, oral liquids, and powders
Targeting a 10% reduction in energy and water consumption, and a 30% cut in carbon emissions across facilities by 2025
Subscribe To Our Newsletter & Stay Updated
